2 recruiting, 1 active not recruiting. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow EIK1001: new trials by email Literature Review of EIK1001 trials Research Report on EIK1001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. EIK1001, Pembrolizumab (KEYTRUDA®), Placebo - Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 750 | 2026-06-15 | 2026-10-20 |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. EIK1001, Pembrolizumab (KEYTRUDA® ) - Advanced Melanoma | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 740 | 2025-05-22 | 2026-10-06 |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC EIK1001, Pembrolizumab, Paclitaxel - NSCLC | Phase 2 | Active not recruiting | Eikon Therapeutics | 70 | 2024-02-06 | 2026-05-28 |
Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1)
United States (3) · Australia (2) · Belgium (2) · Germany (2) · Poland (2) · South Africa (2) · South Korea (2) · Spain (2) · Austria (1) · Canada (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Greece (1)
Etah Kurland (1) · Etah Kurland, MD (1) · Muaz Sadeia (1) · Nishitha Reddy (1)
2025 (1)